Acute Lymphoblastic Leukemia Clinical Trial
Official title:
A Phase I Study of Sirolimus With PEG-Asparaginase in Multiple Recurrent or Refractory Childhood Acute Lymphoblastic Leukemia
The goal of this study is to find a safe dose of sirolimus that can be used with a standard
dose of L-asparaginase. To find the safe dose, the investigators will give the first patient
a very small dose of sirolimus (smaller than the dose used in organ transplant children) and
the standard dose of L-asparaginase. The investigators will then look for side effects. If
side effects develop, the investigators will decrease the dose of sirolimus. If they do not,
the investigators will increase the dose of sirolimus in the next patient on the study. The
investigators will continue this method until fewer than one-third of patients have a side
effect that would require stopping the drug or changing the dose.
The investigators plan to enroll up to 15 children with relapsed ALL. The enrolled patients
must have recovered from other treatment before starting this study. Also, they cannot have
severe side effects from their earlier therapy that will possibly make these drugs less
safe.
The investigators will collect information on whether these drugs help to cure the ALL, but
the purpose will be to find a dose of sirolimus that does not cause too many side effects
when combined with L-asparaginase. This will be explained to the families and they will sign
a written consent. The patients will provide either verbal or written assent when
appropriate.
Multiple relapsed acute lymphoblastic leukemia (ALL) has a very poor cure rate, and there is
no standard of care for treatment of these patients. Therefore, we want to combine two
chemotherapy drugs to see if they are safe and will help treat these patients. The first
agent, L-asparaginase, is used in most patients during their initial treatment for ALL. The
second agent, sirolimus, causes death in human leukemia cells in the laboratory. Sirolimus
is also used in children who have received kidney or heart transplants to prevent organ
rejection. Therefore, the safety and side effects are well known in children.
There are many steps that allow cancer cells to grow in humans. L-asparaginase and sirolimus
block two different steps in cell growth. Because of this, we anticipate that these two
drugs will work together to lead to more cancer cell death.
The first part of the study will last 1 month for each patient. If the patients have a good
response to these two drugs, they will be allowed to continue these drugs for up to 12
months. They will continue on the dose of sirolimus that they received during the first
month for the remaining time on the study.
We will also look at the way leukemia cells are responding to these medications in the
laboratory. We will not draw any blood or bone marrow samples from the patient unless they
already need the procedure done for other tests. The amount of extra blood or bone marrow
drawn will not cause the patients any harm. As we do not know what these laboratory tests
mean, we will not tell the patients the results during the study.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |